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Khalilidehkordi et al. NMOSD Relapses
Neuromyelitis optica spectrum disorders (NMOSD) and multiple sclerosis (MS) show
overlap in their clinical features. We performed an analysis of relapses with the aim of
determining differences between the two conditions. Cases of NMOSD and age- and
sex-matched MS controls were collected from across Australia and New Zealand.
Demographic and clinical information, including relapse histories, were recorded using
a standard questionnaire. There were 75 cases of NMOSD and 101MS controls. There
were 328 relapses in the NMOSD cases and 375 in MS controls. Spinal cord and optic
neuritis attacks were the most common relapses in both NMOSD and MS. Optic neuritis
(p < 0.001) and area postrema relapses (P = 0.002) were more common in NMOSD and
other brainstem attacks were more common in MS (p < 0.001). Prior to age 30 years,
attacks of optic neuritis were more common in NMOSD than transverse myelitis. After
30 this pattern was reversed. Relapses in NMOSD were more likely to be treated with
acute immunotherapies and were less likely to recover completely. Analysis by month of
relapse in NMOSD showed a trend toward reduced risk of relapse in February to April
compared to a peak in November to January (P = 0.065). Optic neuritis and transverse
myelitis are the most common types of relapse in NMOSD and MS. Optic neuritis tends
to occur more frequently in NMOSD prior to the age of 30, with transverse myelitis being
more common thereafter. Relapses in NMOSD were more severe. A seasonal bias for
relapses in spring-summer may exist in NMOSD.
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INTRODUCTION
Neuromyelitis optica spectrum disorders (NMOSD) have been
recognized as having a distinct clinical and radiological
phenotype which helps to differentiate these patients from those
with multiple sclerosis (MS) (1). Early studies had indicated
that the pathology of these two disorders was quite distinct,
with NMOSD being more destructive (2). The identification
of antibodies to the water channel aquaporin-4 (AQP4) in a
significant proportion of patients with NMOSD (3) has greatly
aided the diagnosis and treatment of this condition. The response
to both acute relapse treatments and long-term preventive
therapies are quite different for NMOSD and MS.
We have previously reported on the incidence and prevalence
(4), AQP4 antibody assay findings (5) and clinical features (6) of a
sizeable cohort of NMOSD cases meeting the 2015 International
Panel for NMODiagnosis (IPND) diagnostic criteria (1) collected
from Australia and New Zealand. Here we analyze the specific
details of relapse patterns, use of acute therapies and temporal
patterns both in relation to the calendar year and across the
lifespan of the disease. These data are compared with an age- and
sex-matched cohort of MS cases collected from the same region
with the aim of identifying distinct patterns of relapse that might
further assist in the early identification of cases of NMOSD and
provide information about potential trigger factors.
METHODS
Case Ascertainment
This was a retrospective case-control study of NMOSD cases and
MS controls. Cases of suspected NMOSD and MS were referred
by a network of 23 clinical centres in Australia and New Zealand
specializing in the assessment of patients with inflammatory
diseases of the central nervous system in both adult and pediatric
populations as previously described (4, 6). Cases of NMOSD
were defined according to the 2015 IPND criteria (1). Testing
for AQP4 antibodies was undertaken using either a tissue-based
immunofluorescence technique or positivity on a least two cell-
based assays (fixed, Euroimmun R© or live, Oxford) as previously
described (5). Testing for MOG antibodies was conducted using
a live cell-based assay as previously described (5). Age- and
sex-matched MS cases were identified from each centre with
the diagnosis of MS being confirmed according to the 2010
McDonald criteria (7) with the added requirements of having
no clinical features suspicious for NMOSD and being negative
for AQP4 antibodies. Basic demographic and clinical features
were recorded for all cases and controls as per a standardized
data collection questionnaire as previously described (6). All
participants provided written informed consent and the study
was approved by the human research ethics committee of all
participating institutions.
Relapse Definitions
For relapses, data regarding the date of onset, symptoms
experienced, presumed lesion location, treatment (intravenous
steroids, plasma exchange, or intravenous gammaglobulin),
maximal expanded disability status scale (EDSS), visual acuity,
extent of recovery (full, partial or none), laterality (unilateral,
bilateral or multicentric) was recorded for each relapse. Details of
symptoms were provided by the participants and where available
corroborated by reference to contemporaneous medical records
and MR imaging findings. The precision for the date of onset
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was recorded as being either the day (date confirmed by medical
records or patient diary reference), month (patient recollection
or indirect medical records) or year (patient recollection).
Lesion locations were based on symptomatology according to
the following conventions. Motor, sensory, bladder, and pain
symptoms in the limbs were attributed to a lesion of the spinal
cord, unless there were additional brainstem or cerebral signs,
or there was evidence of an active lesion elsewhere on MR
imaging that could account for the symptoms in the absence of
a relevant lesion in the spinal cord. Symptoms in the limbs with
either ataxia, vestibular symptoms or cranial nerve signs were
deemed to be a lesion of the brainstem/cerebellum. Hemi-motor
or sensory symptoms were attributed to a lesion of the cerebral
hemisphere where there was involvement of the face, cortical
signs or a relevant hemispheric lesion. Blurring of vision in one
or both eyes was deemed to be due to a lesion of the optic nerve,
chiasm or tracts, unless there were additional brainstem signs.
If symptoms could not be attributed to a single lesion site or if
there was evidence of multiple active lesions on MR imaging,
then lesions were deemed to be multifocal and assigned to the
smallest number of regions required to explain all the symptoms.
Episodes of hiccoughs, nausea and vomiting with a lesion of
the area postrema evident on MR imaging were counted as
area postrema relapses. Encephalitic presentations were defined
as focal hemispheric symptoms or a focal hemispheric lesion
associated with seizures, headache or clouding of consciousness.
Classical Devic presentations were defined as the simultaneous
or sequential onset (within 3 months) of optic neuritis and
transverse myelitis (8).
Statistical Analysis
Frequencies are expressed as n/N (%) and continuous data are
presented as median (range) if not normally distributed or mean
(SD) if normally distributed. Comparisons between NMOSD
and MS have been made using appropriate parametric or non-
parametric tests. For categorical variables, Fisher’s exact test
was used when the number of patients in any cell was less
than five. No correction for multiple testing was undertaken.
These statistical tests were performed using Statistical Package
for Social Science (SPSS R©) v25 (IBM R©; Chicago, US). Auto
regressive integrated moving average time series method was
used to analyze the effect of month and seasons in the time series
to predict the occurrence of relapse in MS. Relapse counts were
analyzed by month using a Poisson regression model with the
median month of relapse used as the reference, as has been used
previously in MS (9). These analyses were performed using the
STATA R© statistical package v14 (StataCorp R©; College Station,
Texas, US).
RESULTS
NMOSD Cases and MS Controls
There were 75 cases of NMOSD with full clinical data that met
the 2015 IPND criteria (1), of which 68 (91%) were positive for
AQP4 antibodies. There were 101 controls with MS who were
all negative for AQP4 antibodies and met the 2010 McDonald
criteria (7). Testing for MOG antibodies was conducted on 42/75
(56%) of NMOSD cases, including all of the seronegative cases
TABLE 1 | Comparison of clinical features of NMOSD and MS.
Clinical feature NMOSD MS p-value
N 75 101
Age (Years)–median (range) 47 (19–85) 46 (16–73) ns
Gender (Female)–n/N (%) 68/75 (91) 86/101 (85) ns
Age at Onset (Years)–median (range) 40 (13–85) 32 (6–59) 0.001
Disease Duration (Years)–median 4.1 (0.1–43.1) 12.3 (0.5–43.3) <0.001
(range)
Relapses–median (range) 4 (1–16) 3 (0–11) ns
Annualized relapse rate–median 0.77 (0.13–3.33) 0.33 (0.06–3.78) <0.001
(range)
EDSS–median (range) 4 (0–9) 2 (0–9) <0.001
Clinical Course–n (%) ns
Monophasic (CIS) 10 (13) 12 (12)
Relapsing remitting 63 (84) 73 (72)
Secondary progressive 2 (3) 13 (13)
Primary progressive 0 (0) 3 (3)
Classical Devic presentation–n (%) 12 (16) 9 (9) ns
With bilateral optic neuritis 4/12 (33) 2/9 (22) ns
Sequential (≤3 months) 6/12 (50) 1/9 (11) ns
Recurrent 2/12 (17) 3/9 (33)
Initial MR brain imaging 12/70 (17) 3/100 (3) 0.001
normal–n/N (%)
LESCL on MR spine 48/71 (68) 1/89 (1) <0.001
imaging–n/N (%)
NMOSD, neuromyelitis optica; MS, multiple sclerosis; LESCL, longitudinally extensive
spinal cord lesion; CIS, clinically isolated syndrome; SD, standard deviation; EDSS,
expanded disability status scale; ns, non-significant.
and 52/101 (51%) of MS controls, and all were negative (5). The
demographic and clinical features of the NMOSD cases and MS
controls have been previously reported (6) and show that they
were well matched for age and sex, but differ in a number of
predictable clinical features as summarized in Table 1. Age of
onset inMS cases was younger and consequently disease duration
was longer. Despite this the number of relapses seen in NMOSD
was greater, although not significantly, and the annualized relapse
rate was approximately double that of MS controls (p < 0.001).
The distribution of numbers of relapses in the two groups is
illustrated in Figure 1. The level of disability at last review was
greater in NMOSD compared to MS (median EDSS 4.0 vs. 2.0;
p < 0.001). Secondary progressive disease was only seen in two
cases of NMOSD and primary progressive NMOSDwas not seen.
The proportion of cases with monophasic disease was similar for
NMOSD and MS although the extent of follow up for the MS
cases was greater. The proportion of NMOSD cases experiencing
a classical Devic presentation showed a trend toward being
higher than in MS and these presentations were more likely to
involve bilateral optic neuritis or be sequential in NMOSD, but
were more commonly recurrent in MS. However, none of these
differences were statistically significant due to the small numbers.
Types of Relapse
The frequency of different relapse types and lesion locations
is summarized in Table 2. The proportions of relapse locations
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FIGURE 1 | Histogram showing distribution of numbers of relapses seen in NMOSD and MS. NMOSD, neuromyelitis optica spectrum disorder; MS, multiple sclerosis.
TABLE 2 | Frequency of relapse locations in NMOSD and MS.
Relapse syndrome First relapse All relapses
NMOSD MS p-value NMOSD MS p-value
n 75 101 329 375
Transverse myelitis 33 (44) 51 (50) ns 159 (48) 165 (44) ns
Optic neuritis 29 (38) 12 (12) <0.001 131 (40) 62 (16) <0.001
Area postrema syndrome 7 (9) 0 (0) 0.009 11 (3) 0 (0) 0.002
Other brainstem syndrome 3 (4) 25 (25) <0.001 16 (5) 90 (24) <0.001
Optic neuritis and transverse myelitis 2 (2) 3 (3) ns 7 (2) 14 (4) ns
Cerebral syndrome 0 (0) 5 (5) ns 2 (1) 15 (4) ns
Optic neuritis and brainstem syndrome 0 (0) 2 (2) ns 2 (1) 9 (2) ns
Brainstem syndrome and transverse myelitis 1 (1) 0 (0) ns 1 (0.3) 0 (0) ns
NMOSD, neuromyelitis optica; MS, multiple sclerosis; ns, non-significant.
at first relapse and for all relapses were similar within the
two cohorts (Table 2). However, there was a difference between
NMOSD cases and MS controls in the frequency of optic
neuritis (p < 0.001) and brainstem lesions (p < 0.001). Optic
neuritis and area postrema lesions were more common in
NMOSD and other brainstem lesions were more common
in MS. Cerebral syndromes were rare in NMOSD and there
was a trend toward these being more common in MS, but
the overall numbers were lower, and this difference was not
significant. There was only one encephalitis presentation seen
in NMOSD. Area postrema syndromes were more common
as a first relapse (9%) compared to all relapses (3%). There
were no cases of NMOSD that presented with hypothermia,
drowsiness or syndrome of inappropriate anti-diuretic hormone
syndrome. When analyzed by sex and serostatus there were no
significant differences in the pattern of relapse in NMOSD (data
not shown).
The frequency of lesion location in NMOSD according to age
at the time of relapse for all relapses is shown in Figure 2 and
indicates that episodes of optic neuritis predominate at a younger
age with a peak age at 20–29 years, whilst attacks of transverse
myelitis predominate later with a peak incidence at 40–49 years.
Relapses of all types were seen across a broad range of ages
(10–69 years).
Relapse Features, Treatment and
Outcomes
The principal features, treatment and outcomes for all relapses in
NMOSD and MS are given in Table 3. The time between relapses
was shorter in NMOSD (10.6 months) compared with MS (18.0
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FIGURE 2 | Frequency of relapse lesion locations according to age at the time of relapse in NMOSD. NMOSD, neuromyelitis optica spectrum disorder; TM, transverse
myelitis; ON, optic neuritis; BS, brainstem/cerebellar; AP, area postrema; CB, cerebral.
months). There was no difference in the proportion of optic
neuritis attacks that were bilateral in NMOSD and MS, but the
absolute frequency was higher in NMOSD (21 vs. 8). Spinal cord
relapses were more commonly partial in MS. Relapse duration
and maximal disability level were greater in NMOSD. NMOSD
cases were more likely to be treated with high dose intravenous or
oral steroids, plasma exchange and intravenous immunoglobulin.
Complete recovery from a relapse was more common (p< 0.001)
in MS (56%) than NMOSD (29%).
Seasonal Variation in Relapses
The seasonal pattern of relapses in NMOSD is shown in Figure 3.
The auto regressive integrated moving average analysis indicated
a marginal significance of month on number of relapses per
month with coefficient = 0.531 C95% CI−0.678 – 1.13, P =
0.082) and adjusted coefficient= 3.677 (95% CI 2.034–5.320, P <
0.001). Poisson regression analysis indicated that no individual
month significantly deviated from the median (Figure 3).
Analysis of 3-month époques indicated a trend toward fewer
relapses in February to April compared to November to January
(P = 0.065). This corresponds to a potential peak risk of relapse
in mid-spring and summer in the Southern Hemisphere and
is similar to the pattern seen in MS for this part of the world
(10) which has been attributed to a 1–2 month lag in relapses
after the nadir of vitamin D levels (September in the Southern
Hemisphere) (10).
DISCUSSION
The present data indicate that the commonest relapse types
seen in NMOSD are transverse myelitis and optic neuritis and
TABLE 3 | Comparison of relapse features, treatment and outcomes in NMOSD
and MS.
Relapse feature NMOSD MS p-value
N 328 375
Time between relapses 10.6 (0.3–336.0) 18.0 (0.5–408.4) <0.001
(months)–median (range)
Bilateral optic neuritis–n/N (%) 21/116 (18) 8/55 (15) ns
Partial cord syndrome– n/N (%) 55/134 (41) 80/148 (54) 0.03
Relapse duration (days)–mean* (range) 68 (2–666) 50 (1—365) <0.001
Maximal EDSS–median (range) 4 (1–10) 3 (1–8) <0.001
Treated with IVMP–n (%) 193 (59) 149 (40) <0.0001
Treated with PLEX–n (%) 41 (13) 0 (0) <0.0001
Treated with IVIg–n (%) 20 (6) 2 (1) <0.0001
Outcome– n/N (%) <0.0001
Complete recovery 78/271 (29) 165/295 (56)
Partial recovery 170/271 (63) 109/295 (37)
No improvement 23/271 (8) 21/295 (7)
*Mean is given in place of median which was 30 days (1 month) for both NMOSD and MS.
NMOSD, neuromyelitis optica spectrum disorder; MS,multiple sclerosis; EDSS, expanded
disability status scale; IVMP, intravenous methylprednisolone or very high dose oral
steroids; PLEX, plasma exchange; IVIg, intravenous immunoglobulin; ns, non-significant.
that optic neuritis attacks, particularly as first attacks, are more
common in NMOSD than MS. Area postrema presentations
were exclusively seen in NMOSD and accounted for 9% of first
relapses and 3% of all relapses. Attacks of optic neuritis were
seen more frequently at a younger age in NMOSD with episodes
of transverse myelitis occurring more frequently later. Relapse
frequency, duration and severity, together with the requirement
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FIGURE 3 | Rate ratio of relapses per month, using median of 29 relapses per month (September). Error bars show 95% confidence intervals (Poisson regression
analysis). Y-axis plotted on logarithmic scale.
for acute immunotherapies, were all greater in NMOSD than
MS. In the situation where the diagnosis of NMOSD had been
established there would be a potential bias toward the use of
acute immunotherapies.
As with previous studies the most frequent form of relapse
in NMOSD was a lesion of the spinal cord and the frequency
observed in the present study (48%) falls in the middle of
previous observations (36–63%) (11–15). The frequencies of
other relapse types were similar to these prior studies. As with
previous studies relapses with encephalitic or other cerebral
features were uncommon in NMOSD. Area postrema lesions as
an initial presenting feature was seen in (9%) which was similar
to prior studies (15). We found that area postrema relapses
were more common at first presentation than with subsequent
relapses. This finding is contrary to a recent larger study of several
international cohorts (16). However, we note the definition for
area postrema syndrome used in that study was broader than
the definition used in the present study. No relapses involving
hypothermia (17) or syndrome of inappropriate anti-diuretic
hormone syndrome (18) were seen in our cohort.
Despite being an inclusion criterion for suspected NMOSD
in our original clinical survey, there were eight optic neuritis
attacks in ourMS cohort that were bilateral. These were historical
attacks and the lesion location was based on symptomatology
which can be prone to error. For example, bilateral visual
blurring can arise as a result of mild diplopia from a brainstem
lesion or a homonymous field deficit due to a cerebral lesion.
These cases otherwise had features typical for MS and were
therefore not reclassified. Classical Devic presentations with
either simultaneous or sequential optic neuritis and transverse
myelitis were only marginally more common in NMOSD than
MS and this was not a significant difference. Classical Devic
presentations were seen in 16% of NMOSD cases. The exclusion
from the MS controls of cases with features suspicious for
NMOSD could potentially introduce a bias in the relapse features
reported here. However, we would note that the number of cases
referred with NMOSD-like features that did not meet 2015 IPND
criteria was similar to the number of confirmed NMOSD cases
in our original survey (6), thus representing no more than 1%
of all MS cases. This is unlikely to introduce any significant
bias. Recall bias is always a potential issue with retrospectively
collected relapse data. However, the methods used in this study
were identical for the NMOSD cases and MS controls.
The frequency with which high dose steroids were
administered for attacks of NMOSD (58%) was higher than
in MS and was similar to previous studies (65–84%) (12, 13). The
frequency of complete recovery was lower in NMOSD than MS
and was in a range similar to that observed previously (13).
Two novel findings in the present study are the observation
that attacks of optic neuritis predominate in younger patients
with NMOSD whilst transverse myelitis is more common
later in life and that there is a seasonal variation in
the frequency of attacks. An earlier study has noted the
predominance of optic neuritis in first presentations prior
to the age of 30 years, with transverse myelitis being more
common above 30 (19). We are not aware of prior data
looking at seasonal variability of relapses in NMOSD. A
trend toward fewer relapses from February to April compared
to a peak from November to January is similar to the
pattern seen in MS both in the Northern and Southern
Hemisphere (9, 10). This finding is somewhat surprising
considering the absence of a latitudinal gradient seen in two
national studies of NMOSD prevalence (4, 20). This suggests
that relative vitamin D deficiency or decreased ultraviolet
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B radiation exposure are not significant factors in the risk
of developing NMOSD but may be factors influencing the
likelihood of relapses. These findings require confirmation in
further studies.
In conclusion, we have confirmed the findings of prior studies
with regard to the pattern of relapses and clinical features seen
in NMOSD. We have shown that this pattern differs significantly
from MS in a number of areas. There was no difference in the
frequency of classical Devic presentations between NMOSD and
MS, but there was a trend toward sequential and bilateral optic
neuritis Devic’s presentations being more common in NMOSD.
The finding of optic neuritis attacks occurring more commonly
at a younger age is interesting and as with the sequential
optic nerve involvement with later spinal cord disease seen in
classical Devic’s syndrome suggests a specific vulnerability of the
optic nerve early in the disease course. The increased risk of
NMOSD relapse during the spring-summer suggests a seasonally
dependent environmental risk factor influencing the timing of
relapses in NMOSD.
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